Is PT-141 (Bremelanotide) Legal in Kentucky? How to Access It Legally
HealthRX.com
Vyleesi is the only legal, prescription-only bremelanotide
Key numbers
- 1.75 mgStrength of the FDA-approved Vyleesi autoinjector, prescription only, for premenopausal women with HSDDSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 45 minutesMinimum time before anticipated sexual activity to inject a Vyleesi dose, per the labelSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 8 doses a monthMaximum number of Vyleesi doses allowed in one month, per the labelSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
See the public record for Bremelanotide
At a glance
- FDA-approved product / Vyleesi (bremelanotide) 1.75 mg subcutaneous autoinjector [1]
- Approved use / Premenopausal women with acquired, generalized HSDD [1]
- Not approved for / Men, postmenopausal women, or enhancing sexual performance [1]
- Prescription / Required [1]
- Compounded or research-use PT-141 / Not Vyleesi; not an FDA-approved drug [1][3]
- Boxed warning / None; no REMS in the label or the 2019 approval letter [1][2]
- Kentucky-specific rules / Not described; federal position only
What is PT-141?
PT-141 is another name for bremelanotide. Bremelanotide was FDA-approved as Vyleesi (NDA 210557) on June 21, 2019, and is sold only by prescription as a 1.75 mg subcutaneous autoinjector [1][2]. The approved use is premenopausal women with acquired, generalized HSDD, meaning low sexual desire that causes marked distress or interpersonal difficulty and is not due to a medical or psychiatric condition, relationship problems, or a medication or drug [1]. The label says Vyleesi is not indicated for HSDD in postmenopausal women or in men, and not to enhance sexual performance [1].
Bremelanotide is a cyclic peptide of 7 amino acids and a melanocortin receptor agonist; how it improves HSDD is unknown [1].
How is it accessed legally?
Through a prescription for Vyleesi. The label directs 1.75 mg subcutaneously into the abdomen or thigh, as needed, at least 45 minutes before anticipated sexual activity, no more than one dose in 24 hours and no more than 8 doses a month, and says to stop after 8 weeks if there is no improvement in symptoms [1]. Vyleesi is contraindicated in uncontrolled hypertension or known cardiovascular disease, and the label says to avoid using it with oral naltrexone products for alcohol or opioid addiction [1].
PT-141 sold as a compounded or research-use peptide is not Vyleesi and is not an FDA-approved drug; compounded drugs are not reviewed by FDA for safety, effectiveness or quality before marketing [3][1]. Bremelanotide does not appear on FDA's list of bulk substances that may present significant safety risks, in any category of FDA's bulk-substance lists, or among the six peptides in HHS's October 2026 draft enforcement-discretion policy [4][5][6].
Questions worth asking
What does the label say to watch for?
Each dose transiently raises blood pressure and lowers heart rate; in clinical studies the maximal increases were 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after the dose, and values usually returned to baseline within 12 hours [1]. In pooled phase 3 trials of 1,247 women, nausea was reported by 40.0% on Vyleesi versus 1.3% on placebo, flushing by 20.3% versus 0.3%, and headache by 11.3% versus 1.9% [1]. Focal hyperpigmentation was reported by 1% of patients taking up to 8 doses a month versus none on placebo; it was more likely with darker skin and daily dosing, and resolution after stopping Vyleesi was not confirmed in all patients [1].
Check what you know
Question 1 of 4
Score: 0 right, 0 of 4 answered
Frequently asked questions
Is PT-141 legal in Kentucky?
Do I need a prescription for bremelanotide?
Is Vyleesi approved for men?
References
Show all 6 referencesHide references
- U.S. National Library of Medicine, DailyMed. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector prescribing information. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector label
- U.S. Food and Drug Administration.
- Official web page.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- Official web page.